Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alemtuzumab + busulfan + fludarabine
- Development stage
- Unknown
- Lead developer
- University of Cambridge
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Alemtuzumab + busulfan + fludarabine is a reduced-toxicity conditioning regimen used before allogeneic hematopoietic stem cell transplantation (HSCT). This combination therapy helps decrease transplantation-related toxicity while improving engraftment rates. The regimen typically consists of targeted intravenous busulfan, fludarabine administered over several days, and alemtuzumab (a monoclonal antibody targeting CD52). This conditioning approach has shown efficacy in patients with various malignant and nonmalignant diseases, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and hemophagocytic lymphohistiocytosis (HLH). The regimen allows for consistent engraftment with reduced rates of graft-versus-host disease (GVHD).
- Other names
- FluBuCam
02
Targets
CD52 (CD52 Antigen)DNA
Beyond the preview
Go deeper on alemtuzumab + busulfan + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alemtuzumab + busulfan + fludarabine.